IP Library › Granted Patent US 8,354,249
Granted Patent B2
US 8,354,249 · App. 11/201,282 · Granted Jan 15, 2013

Intravenous immunoglobulin composition

Inventors: Israel Nur (Moshav Timurim, IL); Liliana Bar (Rehovot, IL); Orgad Laub (Tel-Aviv, IL)
Assignee: Omrix Biopharmaceuticals Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,354,249
App. No.
11/201,282
Granted
Jan 15, 2013
Kind
B2
Abstract

A method for preparing a concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, comprising: (a) selecting a population of individuals previously vaccinated against one or more antigens associated with the pathogenic microorganism; (b) determining the level of specific antibodies immunoreactive with the pathogenic microorganism in a blood or blood component of the individuals to identify very high titre individuals having a very high titre of the specific antibodies; (c) combining blood or blood components comprising immunoglobulins from the very high titre individuals; and (d) purifying and/or concentrating the product of step (c), thereby obtaining a concentrated immunoglobulin composition. Also disclosed is a concentrated immunoglobulin composition comprising specific antibodies immunoreactive with a pathogenic microorganism, characterized in that the titre of specific antibodies of the composition is at least 5 times higher than the average titre of specific antibodies of a population of individuals previously vaccinated against one or more antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates, and is therefore suitable for both iv and im administration. In a preferred embodiment, the pathogenic microorganism is smallpox virus or vaccinia virus.

Claims (36)

1. A method for preparing a concentrated immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, comprising:

(a) selecting a population of at least 50 individuals revaccinated against one or more antigens associated with the pathogenic microorganism;

(b) identifying very high titre individuals from said population having a very high titre of specific antibodies immunoreactive with one or more antigens associated with said pathogenic microorganism by an immunoassay in a blood or blood component of said individuals, wherein said very high titre individuals are defined as those of the highest responders whose pooled blood or blood components have an average titre of said specific antibodies that is at least five times higher than the average titre of said specific antibodies of the pooled blood or blood components of the entire population of step (a);

(c) combining blood or blood components comprising immunoglobulins from said very high titre individuals; and

(d) purifying and/or concentrating the product of step (c), to obtain a concentrated immunoglobulin composition.

2. The method of claim 1 , further comprising the step of aliquoting the concentrated immunoglobulin composition in a low-volume unit dosage form.

3. The method of claim 2 , wherein said low-volume unit dosage form comprises a vial or a pre-filled syringe.

4. The method of claim 1 , wherein said pathogenic microorganism is a virus.

5. The method according to claim 4 , wherein said virus is a vaccinia virus.

6. The method according to claim 1 , wherein the titre of specific antibodies of the concentrated immunoglobulin composition is at least 10 times higher than the average titre of specific antibodies of said revaccinated population.

7. The method of claim 1 , wherein the concentrated immunoglobulin composition contains at least approximately 10% immunoglobulin.

8. The method according to claim 1 , wherein blood or blood components are repeatedly obtained from each of said high titre individuals.

9. The method of claim 1 , wherein said blood component is plasma.

10. A method for preparing a concentrated immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, comprising:

(a) selecting a population of at least 50 individuals revaccinated against one or more antigens associated with the pathogenic microorganism, which antigens elicit specific antibodies against said pathogenic microorganism;

(b) identifying very high titre individuals from said population having a very high titre of said specific antibodies by an immunoassay in a blood or blood component of said individuals, wherein said very high titre individuals are defined as those of the highest responders whose pooled blood or blood components have an average titre of said specific antibodies that is at least five times higher than the average titre of said specific antibodies of the pooled blood or blood components of the entire population of step (a);

(c) combining blood or blood components comprising immunoglobulins from said very high titre individuals; and

(d) purifying and/or concentrating the product of step (c), to obtain a concentrated immunoglobulin composition.

11. The method of claim 10 , further comprising the step of aliquoting the concentrated immunoglobulin composition in a low-volume unit dosage form.

12. The method of claim 11 , wherein said low-volume unit dosage form comprises a vial or a pre-filled syringe.

13. The method of claim 10 , wherein said pathogenic microorganism is a virus.

14. The method according to claim 13 , wherein said virus is a vaccinia virus.

15. The method according to claim 10 , wherein the titre of specific antibodies of the concentrated immunoglobulin composition is at least 10 times higher than the average titre of specific antibodies of said revaccinated population.

16. The method of claim 10 , wherein the concentrated immunoglobulin composition contains at least approximately 10% immunoglobulin.

17. The method according to claim 10 , wherein blood or blood components are repeatedly obtained from each of said high titre individuals.

18. The method of claim 10 , wherein said blood component is plasma.

19. A method for preparing a concentrated immunoglobulin composition for treating subjects infected with a pathogenic microorganism, comprising:

(a) selecting a population of at least 50 individuals revaccinated against one or more antigens associated with the pathogenic microorganism;

(b) identifying very high titre individuals from said population having a very high titre of specific antibodies immunoreactive with one or more antigens associated with said pathogenic microorganism by an immunoassay in a blood or blood component of said individuals, wherein said very high titre individuals are defined as those of the highest responders whose pooled blood or blood components have an average titre of said specific antibodies that is at least five times higher than the average titre of said specific antibodies of the pooled blood or blood components of the entire population of step (a);

(c) combining blood or blood components comprising immunoglobulins from said very high titre individuals; and

(d) purifying and/or concentrating the product of step (c), to obtain a concentrated immunoglobulin composition.

20. A method for preparing a concentrated immunoglobulin composition, comprising:

(a) selecting a population of at least 50 individuals revaccinated against one or more antigens associated with a specified pathogenic microorganism;

(b) identifying very high titre individuals from said population having a very high titre of specific antibodies immunoreactive with one or more antigens associated with said pathogenic microorganism by an immunoassay in a blood or blood component of said individuals, wherein said very high titre individuals are defined as those of the highest responders whose pooled blood or blood components have an average titre of said specific antibodies that is at least five times higher than the average titre of said specific antibodies of the pooled blood or blood components of the entire population of step (a);

(c) combining blood or blood components comprising immunoglobulins from said very high titre individuals; and

(d) purifying and/or concentrating the product of step (c), to obtain a concentrated immunoglobulin composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2006
From: NUR, ISRAEL; BAR, LILIANA; LAUB, ORGAD
To: OMRIX BIOPHARMACEUTICALS LTD.
Reel/Frame 017189/0923 →
Continuity (1)
Related Publication 20070037170A1 · Feb 15, 2007